These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 31711919)

  • 1. FAM122A supports the growth of hepatocellular carcinoma cells and its deletion enhances Doxorubicin-induced cytotoxicity.
    Zhou Y; Shi WY; He W; Yan ZW; Liu MH; Chen J; Yang YS; Wang YQ; Chen GQ; Huang Y
    Exp Cell Res; 2020 Feb; 387(1):111714. PubMed ID: 31711919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FAM122A maintains DNA stability possibly through the regulation of topoisomerase IIα expression.
    Wang YQ; Yang YS; Chen J; Liu MH; Chen GQ; Huang Y
    Exp Cell Res; 2020 Nov; 396(1):112242. PubMed ID: 32866497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MiR-26 enhances chemosensitivity and promotes apoptosis of hepatocellular carcinoma cells through inhibiting autophagy.
    Jin F; Wang Y; Li M; Zhu Y; Liang H; Wang C; Wang F; Zhang CY; Zen K; Li L
    Cell Death Dis; 2017 Jan; 8(1):e2540. PubMed ID: 28079894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Knockdown of eukaryotic translation initiation factor 5A2 enhances the therapeutic efficiency of doxorubicin in hepatocellular carcinoma cells by triggering lethal autophagy.
    Tang Y; Chen K; Luan X; Zhang J; Liu R; Zheng X; Xie S; Ke H; Zhang X; Chen W
    Int J Oncol; 2020 Dec; 57(6):1368-1380. PubMed ID: 33174013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein phosphatase 2A-B55δ enhances chemotherapy sensitivity of human hepatocellular carcinoma under the regulation of microRNA-133b.
    Zhuang Q; Zhou T; He C; Zhang S; Qiu Y; Luo B; Zhao R; Liu H; Lin Y; Lin Z
    J Exp Clin Cancer Res; 2016 Apr; 35():67. PubMed ID: 27074866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. WM130 preferentially inhibits hepatic cancer stem-like cells by suppressing AKT/GSK3β/β-catenin signaling pathway.
    Ni CX; Qi Y; Zhang J; Liu Y; Xu WH; Xu J; Hu HG; Wu QY; Wang Y; Zhang JP
    Oncotarget; 2016 Nov; 7(48):79544-79556. PubMed ID: 27783993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiR-101 and doxorubicin codelivered by liposomes suppressing malignant properties of hepatocellular carcinoma.
    Xu F; Liao JZ; Xiang GY; Zhao PX; Ye F; Zhao Q; He XX
    Cancer Med; 2017 Mar; 6(3):651-661. PubMed ID: 28135055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modified AS1411 Aptamer Suppresses Hepatocellular Carcinoma by Up-Regulating Galectin-14.
    Cho Y; Lee YB; Lee JH; Lee DH; Cho EJ; Yu SJ; Kim YJ; Kim JI; Im JH; Lee JH; Oh EJ; Yoon JH
    PLoS One; 2016; 11(8):e0160822. PubMed ID: 27494117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-223 overexpression inhibits doxorubicin-induced autophagy by targeting FOXO3a and reverses chemoresistance in hepatocellular carcinoma cells.
    Zhou Y; Chen E; Tang Y; Mao J; Shen J; Zheng X; Xie S; Zhang S; Wu Y; Liu H; Zhi X; Ma T; Ni H; Chen J; Chai K; Chen W
    Cell Death Dis; 2019 Nov; 10(11):843. PubMed ID: 31695022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Downregulation of Peptidylprolyl isomerase A promotes cell death and enhances doxorubicin-induced apoptosis in hepatocellular carcinoma.
    Cheng S; Luo M; Ding C; Peng C; Lv Z; Tong R; Xiao H; Xie H; Zhou L; Wu J; Zheng S
    Gene; 2016 Oct; 591(1):236-244. PubMed ID: 27397650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-505 enhances doxorubicin-induced cytotoxicity in hepatocellular carcinoma through repressing the Akt pathway by directly targeting HMGB1.
    Lu L; Zhang D; Xu Y; Bai G; Lv Y; Liang J
    Biomed Pharmacother; 2018 Aug; 104():613-621. PubMed ID: 29803174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FAM122A, a new endogenous inhibitor of protein phosphatase 2A.
    Fan L; Liu MH; Guo M; Hu CX; Yan ZW; Chen J; Chen GQ; Huang Y
    Oncotarget; 2016 Sep; 7(39):63887-63900. PubMed ID: 27588481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
    Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
    J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upregulation of the oncoprotein SET determines poor clinical outcomes in hepatocellular carcinoma and shows therapeutic potential.
    Hung MH; Chen YL; Chu PY; Shih CT; Yu HC; Tai WT; Shiau CW; Chen KF
    Oncogene; 2016 Sep; 35(37):4891-902. PubMed ID: 26876205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA-6809-5p mediates luteolin-induced anticancer effects against hepatoma by targeting flotillin 1.
    Yang PW; Lu ZY; Pan Q; Chen TT; Feng XJ; Wang SM; Pan YC; Zhu MH; Zhang SH
    Phytomedicine; 2019 Apr; 57():18-29. PubMed ID: 30668319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells.
    Chen BW; Chen W; Liang H; Liu H; Liang C; Zhi X; Hu LQ; Yu XZ; Wei T; Ma T; Xue F; Zheng L; Zhao B; Feng XH; Bai XL; Liang TB
    Mol Cancer Ther; 2015 Aug; 14(8):1805-15. PubMed ID: 26026051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. linc‑ROR facilitates hepatocellular carcinoma resistance to doxorubicin by regulating TWIST1‑mediated epithelial‑mesenchymal transition.
    Zhang Y; Wu W; Sun Q; Ye L; Zhou D; Wang W
    Mol Med Rep; 2021 May; 23(5):. PubMed ID: 33760121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of miR-1258 contributes to carcinogenesis and progression of liver cancer through targeting CDC28 protein kinase regulatory subunit 1B.
    Hu M; Wang M; Lu H; Wang X; Fang X; Wang J; Ma C; Chen X; Xia H
    Oncotarget; 2016 Jul; 7(28):43419-43431. PubMed ID: 27270326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation.
    Chen KF; Yu HC; Liu TH; Lee SS; Chen PJ; Cheng AL
    J Hepatol; 2010 Jan; 52(1):88-95. PubMed ID: 19913321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Auphen and dibutyryl cAMP suppress growth of hepatocellular carcinoma by regulating expression of aquaporins 3 and 9 in vivo.
    Peng R; Zhao GX; Li J; Zhang Y; Shen XZ; Wang JY; Sun JY
    World J Gastroenterol; 2016 Mar; 22(12):3341-54. PubMed ID: 27022216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.